BOSTON, Sept. 29 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has received purchase orders for the MammoView(TM) line of surgical endoscopy instruments from Beth Israel Medical Center, one of the five Continuum Health Partners health care facilities that play a vital role in providing quality medical care for millions of New Yorkers.
Beth Israel Medical Center has been serving the New York City community since 1889 and has grown into one of the largest providers of inpatient care in New York. Beth Israel Medical Center is made up of two inpatient facilities, the Petrie Division in Manhattan and the Kings Highway Division in Brooklyn, as well as a vast network of ambulatory sites and physician practice settings. With world class specialists in areas including heart disease, cancer, neurology, orthopedics, minimally invasive surgery, women’s health, psychiatry and pain medicine and palliative care, Beth Israel Medical Center is widely known for combining medical excellence with clinically innovative programs. As University Hospital and the Manhattan Campus for the Albert Einstein College of Medicine, Beth Israel remains steadfast in its commitment to the training and education of the clinical leaders of tomorrow.
“We are proud to be a supplier to such a prestigious healthcare provider. The Beth Israel Medical Center has been serving New York City for over 100 years and we look forward to creating a long term relationship with the organization,” stated Bob Segersten, President of Solos Endoscopy, Inc.
For more information on Beth Israel Medical Center, please visit: http://www.wehealny.org/patients/bi_home/bi_index.html
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
CONTACT: Brian Neff, Investor Relations, Big Apple Consulting USA, Inc.,
+1-407-389-5900, for Solos Endoscopy, Inc.
Web site: http://www.solosendoscopy.com/
